SHENZHEN, China, July 1, 2025 /PRNewswire/ -- The 2025 Shenzhen International Optics Fair and Smart Wearable Expo successfully concluded at the Shenzhen Convention and Exhibition Center in Futian District, attracting over 200 exhibitors from more than 20 countries and over 30,000 professional visitors.
Centered on the theme "Traditional Eyewear + Smart Wearables," the three-day event highlights the latest innovations and emerging trends, underscoring Shenzhen's growing stature as a global hub for eyewear manufacturing and technology.
Covering 15,000 square meters, the expo features nine major zones that span the entire eyewear industry value chain. These include a Brand Zone showcasing high-end manufacturing capabilities, an Optometry Zone focusing on cutting-edge vision health technologies, and an AI Eyewear Zone spotlighting pioneering advances in artificial intelligence (AI), augmented reality (AR), and virtual reality (VR).
A standout feature of this year's expo is the "45 Years of Longgang Eyewear Development" exhibition. It chronicles Longgang District's rise from a modest manufacturing hub in 1983 to a global powerhouse in mid-to-high-end eyewear production. The display traces the area's evolution from contract manufacturing to brand creation and smart technology adoption, highlighting Longgang's vital role in the global eyewear industry.
Valerie Riffaud Cangelosi, CEO of French consulting firm REAPSE and a leading European smart glasses expert, highlighted the industry's decade-long efforts to establish benchmarks for smart glasses technology and coordinated global advancements in intelligent eyewear.
The expo also puts a spotlight on the rapidly accelerating integration of AI with traditional eyewear craftsmanship. The dedicated "AI Eyewear Industry Chain Map" zone presents a comprehensive technology ecosystem — from chip design and sensor manufacturing to device assembly — where leading companies showcase their latest innovations. Notably, Loho Group unveiled China's first mass-produced AI smart glasses, which combine features such as photo and video capture, audio recording, translation, object recognition, and human-computer interaction. Powered by mobile internet, big data, and AI, these glasses aim to redefine the user experience.
Consumer AR leader RayNeo introduced new models including the RayNeo X3 Pro, Air 3s, and V3 Slim, which recently topped sales charts on JD.com and Tmall's XR platforms during the 618 online shopping festival. Additional standout AI-enabled products — such as smart camera glasses and intelligent audio eyewear — demonstrate the rapid technological innovation reshaping the sector.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Spotlights smart eyewear innovation: 2025 Shenzhen International Optics Fair and Smart Wearable Expo successfully concluded
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
